Using semaglutide to treat advanced lung disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the feasibility and tolerability of semaglutide, a medication approved for diabetes and obesity, in patients with advanced lung diseases such as interstitial lung disease, COPD, and pulmonary hypertension. The study involves a small group of adults who will undergo pulmonary function tests, physical assessments, and body composition evaluations before and after a 12-week treatment period with semaglutide. Participants will also be monitored for any adverse effects during the therapy. The goal is to determine if patients can tolerate the medication and if it can help them achieve a target weight.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosis of one of the following lung diseases: interstitial lung disease, sarcoidosis, chronic obstructive pulmonary disease, or pulmonary hypertension
* Age \> 18
* BMI \> 30 kg/m2
* Requires supplemental oxygen on exertion
* Stable treatment regimen X 90 days
* Use of disease-modifying therapy

Exclusion Criteria:

* Diabetes
* Pregnant or Breastfeeding
* Recent weight loss
* Recent or chronic GI complaints
* History of gastroparesis
* History of scleroderma
* Hospitalized at time of evaluation
* Use of weight loss medication in last 90 days
* Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia (type 2)
* Uncontrolled thyroid disease
* History of acute/chronic pancreatitis
* Prior suicide attempt
* Suicidal ideation in last 90 days
* Presence of a pacemaker or defibrillator

Where it's running

• University of Pennsylvania Perelman School of Medicine
  Philadelphia, Pennsylvania, United States Recruiting

Study contacts

• Principal investigator: Michaela R Anderson, MD — University of Pennsylvania
• Study coordinator: Michaela R Anderson, MD
• Email: michaela.anderson@pennmedicine.upenn.edu
• Phone: 215-662-3202

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Inhaled mosliciguat for pulmonary hypertension in interstitial lung disease (PH-ILD) patients

  This study tests inhaled mosliciguat versus placebo in people with PH-ILD to see if it helps with their condition.

  Recruiting at 3 sites Phase 3 Pulmovant, Inc. · Kissimmee, Florida and 2 other locations · NCT07816185

• Home exercise for people with pulmonary hypertension and ILD

  A home-based exercise program is tested to see if people with pulmonary hypertension related to interstitial lung disease can improve walking ability and daily function over 16 weeks.

  Recruiting University of Rochester · Rochester, New York · NCT07561034

• Long-Term TPIP Extension for PH-ILD (open-label)

  This study tests whether long-term use of Treprostinil Palmitil Inhalation Powder helps people with pulmonary hypertension due to interstitial lung disease who completed a prior trial.

  Recruiting at 12 sites Phase 3 Insmed Incorporated · Naples, Florida and 11 other locations · NCT07234032

• Once-daily inhaled treprostinil palmitil for pulmonary hypertension linked to interstitial lung disease

  This trial will test whether once-daily inhaled treprostinil palmitil improves exercise ability over 24 weeks in adults with pulmonary hypertension caused by interstitial lung disease.

  Recruiting at 166 sites Phase 3 Insmed Incorporated · Phoenix, Arizona and 185 other locations · NCT07179380

• Registry for patients with pulmonary hypertension linked to interstitial lung disease

  This study is collecting information from patients with pulmonary hypertension linked to interstitial lung disease to see how different treatments affect their health over time.

  Recruiting at 71 sites United Therapeutics · Birmingham, Alabama and 70 other locations · NCT06388421

• SELF-BREATHE: a self-guided online program to reduce chronic breathlessness in adults

  This study will test whether SELF-BREATHE, a self-guided internet-based support program, can help adults with chronic breathlessness from lung or heart conditions breathe easier and feel less distressed.

  Recruiting King's College Hospital NHS Trust · London · NCT06326957

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.